CME Courses
(6 contents)
CME Courses
The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM
CME Courses
An Expert Approach to Cardio-Renal Protection in CKD
CME Courses
The Advancing Management of Transthyretin Amyloidosis: A Practical Guide
CME Courses
Examining a Complex Heart Failure Case
CME Courses
Incorporating GDMT and PRO Endpoints for Personalised Heart Failure Management
CME Courses
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
ESC - August 2024
(5 contents)
ESC 2024
An Expert Assessment on the True Impact of ATTR-CM: Welcome and Introduction
EN
Prof Julian Gillmore welcomes the audience to the symposium, introduces the faculty and announces the first poll.
ESC 2024
A Contemporary View of ATTR-CM Epidemiology
EN
In this session Dr Margot Davis presents on Contemporary View of ATTR-CM Epidemiology covering the diagnostic trends in ATTR-CM, highlighting the incidence of wild-type and hereditary subtypes, and exploring the mixed phenotype.
ESC 2024
Practical Screening: What's the Role of the Cardiologist?
EN
This session, presented by Dr Giuseppe Vergaro covers best practices for screening in general cardiology, including identifying red flags, next steps if ATTR is suspected, and assessing for a mixed phenotype. The session highlights crucial steps in…
ESC 2024
Where Are We Now and What’s Next in Medical Management?
EN
In the final presentation of the symposium, Ahmad Masri will discuss the current medical management of ATTR, highlighting approved therapy classes; the focus will be on silencer treatments. Dr Masri will also explore future clinical trials.
ESC 2024
An Expert Assessment on the True Impact of ATTR-CM: Closing Remarks
EN
The session concludes with a panel discussion and an interactive question and answer session, where the panellists address questions from the audience
HFA - May 2024
(7 contents)
HFA 2024
Management Observations From Real-World Data
EN
Part one of this exclusive discussion 'Reshaping Early Identification and Diagnosis of Heart Failure' recorded live from HFA 2024.
HFA 2024
What Are We Learning From Diagnostic Practices?
EN
Part two of this exclusive discussion 'Reshaping Early Identification and Diagnosis of Heart Failure' recorded live from HFA 2024.
HFA 2024
Practical Implementation of Real-World Data
EN
Part three of this exclusive discussion 'Reshaping Early Identification and Diagnosis of Heart Failure' recorded live from HFA 2024.
HFA 2024
Implementing GDMT: What Should We Be Doing?
EN
Part one of 'A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure', Prof Bayés-Genís presents and explores the best practices and strategies for implementing GDMT in clinical settings.
HFA 2024
Implementing GDMT: What Is Really Happening?
EN
Part two of 'A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure', Dr Anderson follows up on Prof Bayés-Genís' presentation by highlighting current real-world practices.
HFA 2024
The Implication of Delayed Diagnosis and Sub-Optimal GDMT
EN
Part three of 'A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure', Dr Greene examines and highlights the consequences of delayed diagnosis and sub-optimal implementation of GDMT on patient outcomes.
HFA 2024
Panel Discussion & Audience Q&A
EN
In this final part, the panel further explore the topic, providing insights into the challenges related to delays and adoption rates in both community and hospital settings, and the significant impact on patient care.
Videos
(18 contents)
Videos
What is GDMT?
EN
Prof Coats and Dr Kosiborod summarise foundational guideline-directed medical therapy (GDMT) across the spectrum of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). [published December…
Videos
Early Initiation and Better Clinical Outcomes
EN
Prof Coats and Dr Kosiborod discuss the relationship between early initiation of foundational GDMT and better clinical outcomes by exploring recent clinical trial data from STRONG-HF. [published December 2022]
Videos
Achieving Early Uptake of GDMT
EN
Prof Coats and Dr Kosiborod cover practical approaches for ensuring early optimal GDMT in heart failure, such as, the use of electronic health records and protocols for specific patient subgroups. [published December 2022]
Videos
Initiating SGLT-2 Inhibitors
EN
Prof Rosano and Dr Bozkurt examine recent guidelines and consider best practice for initiating SGLT-2 inhibitors across the continuum of HF and in patients already on HF medication versus those who are treatment-naïve. [published January 2023]
Videos
Evolving the Management Approach - AEs and MDTs
EN
Prof Rosano and Dr Bozkurt discuss the practicalities of continual management of HF patients on an SGLT-2 inhibitor and how the broader multidisciplinary team should be aware of the benefits of early SGLT-2 initiation in HF. [published January 2023]
Videos
QoL and Functional Measures of Treatment Success
EN
Dr Kosiborod and Dr Zieroth discuss QoL and functional status as tangible measurements of treatment success. [published March 2023]
Videos
Clinical Evidence
EN
Dr Kosiborod and Dr Zieroth look at the relationship between initiating GDMT and QoL / functional status improvement. They discuss some of the specific clinical trial data showing how initiating SGLT-2 inhibitors improves QoL and functional outcomes…
Videos
Practically Implementing PROMs
EN
Dr Kosiborod and Dr Zieroth discuss practical implication of patient reported outcome measures (PROMs). [published March 2023]
Videos
Implementation Strategies for GDMT in Respect of the New Guidelines
EN
In this short interview, Dr Kosiborod and Dr Van Spall summarise some of the key changes in guidance following the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. [published April 2022]
Videos
The DELIVER Trial in Brief
EN
Prof Lam discusses DELIVER with one of the trial’s lead investigators, Prof McMurray. As well as the key results from DELIVER, they consider how to apply them to HFpEF patients in the real-world. [published August 2022]
Videos
DELIVER and DAPA-HF Pooled Analysis in Brief
EN
Prof Lam and Prof McMurray put into context the pooled analysis of DELIVER and DAPA-HF and consider whether these results can be extrapolated to the entire HF population, addressing the suitability of patients according to their individual EF. …
Videos
Guideline Directed Medical Therapy in HF
EN
In this short peer-to-peer discussion, Dr Biykem Bozkurt, and Prof Giuseppe Rosano, discuss the main updates from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. [published April 2022]
Videos
SGLT-2 Inhibitors Across the Range Of EF
EN
In this short peer-to-peer discussion, Prof Giuseppe Rosano and Dr Mikhail Kosiborod, discuss the main updates from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. [published April 2022]
Videos
Re-Evaluating GDMT in Heart Failure: Part 1 - Accommodating New Evidence in HF Guidelines
EN
Dr Savarese and Dr Bozkurt summarise the 2022 American guidelines new recommendations for pharmacological agents in HF and the evidence that was unavailable in the 2021 European guidelines. [published March 2023]
Videos
Re-Evaluating GDMT in Heart Failure: Part 2 - Current Trends in HF GDMT
EN
Dr Savarese and Dr Vardeny discuss the recent guideline recommendations for four pillar GDMT and how well these are being utilised in clinical practice for patients with HF. [published March 2023]
Videos
HF Guideline Review: Distilling the New ESC Guideline Update
EN
Prof Lam and Prof Rosano discuss why there was a need for an update of the 2021 guidelines, and consider the changing landscape following several randomised controlled trials. [published September 2023]
Videos
HF Guideline Review: Assessing the Impact on Practice
EN
Prof Lam and Prof Rosano consider the recommendations for SGLT2 inhibitor use, to reduce cardiovascular death and heart failure hospitalisation, and the expected impact on clinical practice. [published September 2023]
Videos
HF Guideline Review: The Future of Heart Failure Management
EN
Prof Lam and Prof Rosano discuss the power of early detection in improving outcomes and stress the need for accessible and efficient diagnostic testing for the prevention of heart failure among high-risk patients. [published September 2023]
Cardiorenal Patients
(5 contents)
Cardiorenal Patients
Consolidating RAASi Recommendations in recent HF and CKD Guidelines
EN
Dr Rastogi and Dr Bonanad discuss the importance of RAASi continuation in cardiorenal disease. They also cover the most recent guidelines from ESC, ACC/AHA and KDIGO on hyperkalaemia management and summarise best practice messages. [published June…
Cardiorenal Patients
Emerging Data in Hyperkalaemia - Insights from Real-World Practice
EN
Dr Bonanad invites Dr Rastogi to present key data from the observational ZORA study on hyperkalaemia management and RAASi use in real world practice. [published June 2024]
Cardiorenal Patients
Optimising RAASi GDMT with Novel Potassium Binders
EN
Dr Rastogi and Dr Bonanad discuss the STRONG-HF study and how novel hyperkalaemia management strategies with potassium binders can be used to achieve optimal guideline directed medical therapy in heart failure and CKD. [published June 2024]
Cardiorenal Patients
RAASi Management in CKD/HF: What We Should Be Doing
EN
Dr Shelley Zieroth presents the background and guidelines for RAASi Management in CKD/HF. [published April 2024]
Cardiorenal Patients
RAASi Management in CKD/HF: What Is Happening in The Real World?
EN
Dr Manish Sood shares real-world evidence, common barriers and how to overcome these to optimal GDMT. [published April 2024]
Heart Failure in Focus Podcast
(8 contents)
Podcasts
Episode 8: Making Progress in HFpEF
EN
Dr Muthiah Vaduganathan is joined by Prof Giuseppe Rosano who played a central part in the development of the 2023 European heart failure guideline focussed update and an earlier publication on HFpEF phenotyping. [October 2023]
Podcasts
Episode 7: The Evolving Role of Primary Care in HF
EN
Dr Muthiah Vaduganathan is joined by Prof Xavier Cos, a general practitioner and Chairman of Primary Care Diabetes Europe, to discuss the current and future role of primary care in heart failure (HF). [March 2023]
Podcasts
Episode 6: Cardiorenal Care in Practice
EN
Dr Muthiah Vaduganathan speaks with Dr Kieran McCafferty, Consultant Nephrologist at Barts NHS Health Trust London, about the growing need for effective management strategies in cardiorenal disease. [February 2023]
Podcasts
Episode 5: Functional & QoL Outcomes in a Sea of Clinical Event Data
EN
Dr Vaduganathan is joined by Dr Mikhail Kosiborod, leading expert on Quality of Life (QoL) instruments world-wide, to discuss functional and QoL outcomes of foundational therapies in Heart Failure (HF) and the clinical application of this data. …
Podcasts
Episode 4: Mitigating Clinical Inertia in Heart Failure
EN
Dr Vaduganathan is joined by Dr Tariq Ahmad to discuss the reality of sub-optimal treatment and possible ways forward using behavioural “nudges” embedded within electronic health records. [November 2022]
Podcasts
Episode 3: 4 Onboard: Implementing GDMT
EN
Dr Vaduganathan is joined by Dr Biykem Bozkurt, for the third episode, to discuss some of the most challenging questions around implementing guideline directed medical therapy (GDMT). [October 2022]
Podcasts
Episode 2: Your Questions Answered
EN
Dr Vaduganathan is joined by Prof Carolyn Lam to continue the theme of SGLT-2 inhibitors in heart failure. Listen to them answer your questions about SGLT-2 inhibitors and the practical management of heart failure patients. [September 2022]
Podcasts
Episode 1: Emerging Data from the ESC
EN
Dr Muthiah Vaduganathan is joined by Prof Scott Solomon for the first episode in this new series, Heart Failure in Focus, to discuss the DELIVER data which was released at the ESC Congress 2022 in Barcelona. [August 2022]
Complex Patients
(9 contents)
Complex Patients
Examining a Complex Heart Failure Case: Part 1 - Approaching the Patient
EN
The multidisciplinary panel discuss their initial approach to a patient from the perspective of their different backgrounds and how they can most effectively manage this patient as a team. [published February 2023]
Complex Patients
Examining a Complex Heart Failure Case: Part 2 - Diagnosing the Patient
EN
The panel discuss labelling the patient with a diagnosis, prioritising problems for management and ask who should start foundational therapy of SGLT-2 inhibitors. [published February 2023]
Complex Patients
Examining a Complex Heart Failure Case: Part 3 - Managing the Patient
EN
The panel review poll results from the audience on approach to management, discuss their approach to initiating GDMT and explore overcoming a dip in renal function following SGLT-2 inhibition. [published February 2023]
Complex Patients
Examining a Complex Heart Failure Case: Part 4 - Follow-up & Referral
EN
The panel now discuss the ongoing patient centred care required for this patient, continued investigation and holistic co-management. [published February 2023]
Complex Patients
Examining a Complex Heart Failure Case: Part 5 - Responding to a Changing Patient
EN
The panel discuss how they would continue to manage the patient with foundational therapy as their symptoms, disease severity and comorbidities change over time. [published February 2023]
Complex Patients
Examining a Complex Heart Failure Case: Part 6 - Re-cap and Summary
EN
Prof Coats closes this programme by summarising key learning points from this complex case of HFpEF. [published February 2023]
Complex Patients
Ejection Fraction - How Important Is It Today?
EN
During the first part of this roundtable, chaired by Prof Cowie, our multidisciplinary panel discuss the importance of EF, and analyse survey data. [published January 2022]
Complex Patients
HFrEF and HFpEF Case Review
EN
During the second part of this roundtable, our multidisciplinary panel discuss two patient cases and their treatment strategies based on recent guidelines and data updates. [published January 2022]
Complex Patients
The Expanding Role of Primary Care in Ongoing HF Management
EN
During the final part of this roundtable, the panel discuss the role of primary care in ongoing heart failure management. [published January 2022]
ESC - August 2023
(9 contents)
ESC 2023
Addressing New Guidelines
EN
Part one of 'Implementing Heart Failure Guidelines with Collaborative Care', this symposium provides an update on the latest guideline recommendations in HFpEF and how to implement them effectively in clinical practice.
ESC 2023
Patient Vignette
EN
Part two of 'Implementing Heart Failure Guidelines with Collaborative Care', this session presents a newly diagnosed HFpEF patient and demonstrates barriers to GDMT.
ESC 2023
Early / Rapid Initiation of GDMT
EN
Part three of 'Implementing Heart Failure Guidelines with Collaborative Care', the panel discuss latest guideline recommendations in HFpEF and how to implement them effectively in clinical practice.
ESC 2023
Anticipating Barriers in HFpEF
EN
Part four of 'Implementing Heart Failure Guidelines with Collaborative Care', the panel provide valuable insights into the challenges and barriers faced while adopting new guideline-directed medical therapy for heart failure patients.
ESC 2023
The Heart Failure Team
EN
Part five of 'Implementing Heart Failure Guidelines with Collaborative Care', this session emphasises the significance of cross-functional teams in managing heart failure therapy.
ESC 2023
ATTR – A Multi-system Disease Posing Unique Challenges
EN
Part one of 'The Advancing Management of Transthyretin Amyloidosis: A practical Guide', this symposium provides you with the practical knowledge and tools to implement ATTR-cm effectively in your clinical practice.
ESC 2023
Assessing Cardiac Manifestations of ATTR
EN
Part two of 'The Advancing Management of Transthyretin Amyloidosis: A practical Guide', Dr Grogan uses a patient journey to discuss the cardiac implications of ATTR and the diagnosis and monitoring of symptomatic cases with ATTR-cm.
ESC 2023
Long-term Management
EN
Part three of 'The Advancing Management of Transthyretin Amyloidosis: A practical Guide', Dr Obici focuses on tracking disease progression by evaluating multiple symptoms and their assessment frequency, involving various healthcare professionals.
ESC 2023
What’s in our Future Toolbox?
EN
Part four of 'The Advancing Management of Transthyretin Amyloidosis: A practical Guide', Prof Kristen delves into the realm of innovative pharmacological management.
HFA - May 2023
(3 contents)
HFA 2023
The Urgency to Implement GDMT
EN
In this first session of this symposium entitled 'Overcoming the Challenges in Optimising GDMT in HF', the panel delve into the urgency of implementing GDMT for patients with heart failure.
HFA 2023
Barriers to Achieving Optimal Medical Therapy
EN
In the second session, the panel engage in a thought-provoking discussion about the barriers that impede the achievement of optimal medical therapy.
HFA 2023
Practical Strategies to Implement New Algorithms in GDMT
EN
In the final session, the panel aims to equip attendees with practical strategies to navigate the complexities of implementing new algorithms in GDMT and improving patient care.
ESC - August 2022
(4 contents)
ESC 2022
SGLT2 Inhibitors: Light at the End of the Tunnel
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
ESC 2022
SGLT2 Inhibitors Across the Spectrum of Heart Failure
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
ESC 2022
Practical Considerations for Treating HF With Mildly Reduced and Preserved EP
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
ESC 2022
Implementing Best Practices Across the Spectrum of Heart Failure
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.